One of the areas of interest for our technology development group is nanobodies. These small, single-chain antibodies are particularly attractive for Drosophila research as in addition to being used for standard immune-technologies such as immunoblots and immunostaining of tissues, they can also be expressed in vivo as fusions to fluorescent proteins (‘chromobodies’) or functional domains (e.g., for degradation or re-localization).

Past applications of this technology in Drosophila relied on availability of nanobodies targeting a specific protein or use of nanobodies targeting...